http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109666723-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851 |
| filingDate | 2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109666723-B |
| titleOfInvention | Application of immunodetection point inhibitor based on PDL1/PDL2 super-enhancer |
| abstract | The invention provides application of a PDL1/PDL2 super-enhancer-based immunodetection point inhibitor, which is used for inhibiting mRNA expression and protein expression of PDL1 and PDL2 on the surface of a cell. The invention can make the tumor cell not express PDL1 and PDL2 at high level by gene editing technology or inhibiting the signal path which activates super enhancer PDL1L2-SE, so that the tumor cell can not generate immune escape, the tumor specific immune response of the organism is stimulated, the curative effect is increased, and the side effect is reduced. The invention can be used in combination with immunodetection point inhibitors, reduce the dosage of PDL1 or PD1 antibodies, increase the therapeutic effect and reduce the side effects. The invention can also be used in combination with chemotherapy to increase the efficacy and reduce the side effects. The invention can also be used together with radiotherapy to increase the curative effect and reduce the side effect. |
| priorityDate | 2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 187.